Literature DB >> 16371761

Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency.

Manisha Das1, Wilbert S Aronow, John A McClung, Robert N Belkin.   

Abstract

Cardiovascular morbidity and mortality is high in patients with chronic renal insufficiency. Patients with chronic renal insufficiency have an increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium than patients with normal renal function. These risk factors for cardiovascular morbidity and mortality contribute to the increased incidence of cardiovascular morbidity and mortality seen in patients with chronic renal insufficiency.

Entities:  

Mesh:

Year:  2006        PMID: 16371761     DOI: 10.1097/01.crd.0000148162.88296.9f

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  15 in total

1.  Myeloperoxidase Levels and Its Product 3-Chlorotyrosine Predict Chronic Kidney Disease Severity and Associated Coronary Artery Disease.

Authors:  Farsad Afshinnia; Lixia Zeng; Jaeman Byun; Crystal A Gadegbeku; Maria Chiara Magnone; Carl Whatling; Barbara Valastro; Matthias Kretzler; Subramaniam Pennathur
Journal:  Am J Nephrol       Date:  2017-07-01       Impact factor: 3.754

2.  Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.

Authors:  Peter A McCullough; Timothy Ball; Katy Mathews Cox; Manish D Assar
Journal:  Clin J Am Soc Nephrol       Date:  2016-10-25       Impact factor: 8.237

Review 3.  Atrial Fibrillation and Oral Anticoagulation in Chronic Kidney Disease.

Authors:  Christiane Engelbertz; Holger Reinecke
Journal:  J Atr Fibrillation       Date:  2012-04-14

Review 4.  The Relationship Between Atrial Fibrillation and Chronic Kidney Disease : Epidemiologic and Pathophysiologic Considerations for a Dual Epidemic.

Authors:  David D McManus; Jane S Saczynski; Jeanine A Ward; Khushleen Jaggi; Peter Bourrell; Chad Darling; Robert J Goldberg
Journal:  J Atr Fibrillation       Date:  2012-06-15

5.  The relationship between coronary artery calcium scores and left atrium size in hemodialysis patients.

Authors:  Ismail Baloglu; Kultigin Turkmen; H Zeki Tonbul; N Yılmaz Selcuk
Journal:  Int Urol Nephrol       Date:  2017-05-18       Impact factor: 2.370

Review 6.  Early detection of CKD: the benefits, limitations and effects on prognosis.

Authors:  Adeera Levin; Paul E Stevens
Journal:  Nat Rev Nephrol       Date:  2011-06-28       Impact factor: 28.314

7.  Chronic kidney disease and outcomes in heart failure with preserved versus reduced ejection fraction: the Cardiovascular Research Network PRESERVE Study.

Authors:  David H Smith; Micah L Thorp; Jerry H Gurwitz; David D McManus; Robert J Goldberg; Larry A Allen; Grace Hsu; Sue Hee Sung; David J Magid; Alan S Go
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-05-17

8.  Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin.

Authors:  Hoang M Lai; Wilbert S Aronow; Phoenix Kalen; Sreedhar Adapa; Kaushal Patel; Arvind Goel; Ravi Vinnakota; Savneek Chugh; Renee Garrick
Journal:  Int J Nephrol Renovasc Dis       Date:  2009-11-19

9.  Chronic kidney disease increases cardiovascular unfavourable outcomes in outpatients with heart failure.

Authors:  Arise G S Galil; Hélady S Pinheiro; Alfredo Chaoubah; Darcília M N Costa; Marcus G Bastos
Journal:  BMC Nephrol       Date:  2009-10-21       Impact factor: 2.388

10.  Maxacalcitol (22-Oxacalcitriol (OCT)) Retards Progression of Left Ventricular Hypertrophy with Renal Dysfunction Through Inhibition of Calcineurin-NFAT Activity.

Authors:  Kazunori Inoue; Isao Matsui; Takayuki Hamano; Keiji Okuda; Yasumasa Tsukamoto; Ayumi Matsumoto; Karin Shimada; Seiichi Yasuda; Yusuke Katsuma; Yoshitsugu Takabatake; Masaru Tanaka; Noriko Tanaka; Toshiaki Mano; Tetsuo Minamino; Yasushi Sakata; Yoshitaka Isaka
Journal:  Cardiovasc Drugs Ther       Date:  2020-11-18       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.